ID   NCI-H3122
AC   CVCL_5160
SY   H3122; H-3122; NCIH3122
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN10989614
DR   CCLE; NCIH3122_LUNG
DR   Cell_Model_Passport; SIDM00137
DR   Cosmic; 755472
DR   Cosmic; 914951
DR   Cosmic; 1146912
DR   Cosmic; 2245571
DR   Cosmic-CLP; 1240190
DR   DepMap; ACH-000337
DR   GDSC; 1240190
DR   GEO; GSM253349
DR   GEO; GSM434307
DR   GEO; GSM794370
DR   GEO; GSM1374739
DR   GEO; GSM1374740
DR   GEO; GSM1670238
DR   IGRhCellID; H3122GEO
DR   LINCS_LDP; LCL-1675
DR   NCI-DTP; NCI-H3122
DR   PharmacoDB; NCIH3122_1104_2019
DR   PRIDE; PXD002556
DR   Wikidata; Q54908028
RX   PubMed=11030152;
RX   PubMed=12759538;
RX   PubMed=18594010;
RX   PubMed=20679594;
RX   PubMed=22961666;
RX   PubMed=23344087;
RX   PubMed=24675041;
RX   PubMed=26361996;
RX   PubMed=27397505;
RX   PubMed=29444439;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: EML4-ALK gene fusion (PubMed=18594010).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.36%; East Asian, South=0%; South Asian=1.48%; European, North=65.9%; European, South=31.26% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; PubMed=20679594
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 10,12
ST   D16S539: 11,12
ST   D5S818: 11,12
ST   D7S820: 8,12
ST   TH01: 7,9.3
ST   TPOX: 10
ST   vWA: 16
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 24
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=12759538; DOI=10.1159/000070299;
RA   Fujishita T., Loda M., Turner R.E., Gentler M., Kashii T.,
RA   Breathnach O.S., Johnson B.E.;
RT   "Sensitivity of non-small-cell lung cancer cell lines established from
RT   patients treated with prolonged infusions of paclitaxel.";
RL   Oncology 64:399-406(2003).
//
RX   PubMed=18594010; DOI=10.1158/1078-0432.CCR-08-0168;
RA   Koivunen J.P., Mermel C.H., Zejnullahu K., Murphy C., Lifshits E.,
RA   Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., Lee J.,
RA   Richards W.G., Sugarbaker D.J., Ducko C., Lindeman N., Marcoux J.P.,
RA   Engelman J.A., Gray N.S., Lee C., Meyerson M., Janne P.A.;
RT   "EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung
RT   cancer.";
RL   Clin. Cancer Res. 14:4275-4283(2008).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.H., Diao L., Masrorpour F.,
RA   Shen L., Liu W., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
//
RX   PubMed=23344087; DOI=10.1097/JTO.0b013e318283dcc0;
RA   Kim S., Kim T.M., Kim D.-W., Go H., Keam B., Lee S.-H., Ku J.-L.,
RA   Chung D.H., Heo D.S.;
RT   "Heterogeneity of genetic changes associated with acquired crizotinib
RT   resistance in ALK-rearranged lung cancer.";
RL   J. Thorac. Oncol. 8:415-422(2013).
//
RX   PubMed=24675041; DOI=10.1158/2159-8290.CD-13-0846;
RA   Friboulet L., Li N., Katayama R., Lee C.C., Gainor J.F., Crystal A.S.,
RA   Michellys P.-Y., Awad M.M., Yanagitani N., Kim S., Pferdekamper A.C.,
RA   Li J., Kasibhatla S., Sun F., Sun X., Hua S., McNamara P., Mahmood S.,
RA   Lockerman E.L., Fujita N., Nishio M., Harris J.L., Shaw A.T.,
RA   Engelman J.A.;
RT   "The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small
RT   cell lung cancer.";
RL   Cancer Discov. 4:662-673(2014).
//
RX   PubMed=26361996; DOI=10.1016/j.jprot.2015.09.003;
RA   Grundner-Culemann K., Dybowski J.N., Klammer M., Tebbe A., Schaab C.,
RA   Daub H.;
RT   "Comparative proteome analysis across non-small cell lung cancer cell
RT   lines.";
RL   J. Proteomics 130:1-10(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//